BHV-1100 is under clinical development by Biohaven and currently in Phase II for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase II drugs for Multiple Myeloma (Kahler Disease) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BHV-1100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BHV-1100 is under development for the treatment of multiple myeloma. The drug candidate acts by targeting cells expressing CD38 and is being developed based on Antibody Recruiting Molecules (ARMs) technology. It acts by targeting CD38. It was also under development for the treatment of infectious diseases. It is administered through parenteral route.
Biohaven formerly Biohaven Research, is biopharmaceutical company discovering, developing, and commercializing novel therapies for the treatment of neurological and neuropsychiatric diseases. Biohaven is headquartered in Tortola, British Virgin Islands.
For a complete picture of BHV-1100’s drug-specific PTSR and LoA scores, buy the report here.